Lupin gains as USFDA completes inspection at its Bioresearch Centre without any observations

Lupin is currently trading at Rs. 781.15, up by 4.30 points or 0.55% from its previous closing of Rs. 776.85 on the BSE.

The scrip opened at Rs. 785.00 and has touched a high and low of Rs. 789.65 and Rs. 775.25 respectively. So far 43980 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 720.40 on 28-Mar-2019.

Last one week high and low of the scrip stood at Rs. 782.80 and Rs. 720.40 respectively. The current market cap of the company is Rs. 35475.51 crore.

The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.

United States Food and Drug Administration (USFDA) has successfully completed inspection at Lupin’s Bioresearch Centre (LBC) without any observations. This is the 5th successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility.

The company’s Bioresearch Centre (LBC) conducts the in-vivo and in-vitro bioequivalence studies for company in Pune. This inspection also included review of studies done at the center’s new site at Lupin Research Park, Pune.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Leave a Reply

Your email address will not be published. Required fields are marked *